A photo of Michael Henrickson.

Michael Henrickson, MD, MPH, RhMSUS

  • Director of Telemedicine, Division of Rheumatology
  • Professor, UC Department of Pediatrics
  • Professor, University of Kentucky College of Medicine
I give people the evidence to make their own decisions because I feel this shared-decision model promotes personal investment in the outcome.



As a pediatric rheumatologist, I am attracted to the unknown. I appreciate the challenge of a real mystery and enjoy using my general pediatric skills when I approach unsolved cases. I recently participated in the discovery of a new disease, an ACOX1 mutation-associated, neurodegenerative, auto-inflammatory disease [Chung et al. Neuron 2020 May 20;106(4):589-606.e6]. This work is relevant as we probe the edges of our collective medical knowledge.

Thinking deeply is an intuitive skill for me. I’m drawn to bringing children back to being functional again. My clinical research contributes to identifying the medicines that achieve a person's goals of healing and regaining their ability to be active.

As a dedicated listener, I pay great attention to detail. Solving mysteries means diligently collecting the clues. I also have a co-existing capacity to pull away from the morass of detail to see the big picture emerge. I connect dots for a living; however, I’m not shy about knowing my limits and when to ask for help.

I give people the evidence to make their own decisions because I feel this shared-decision model promotes personal investment in the outcome. If pressed, I will provide an opinion, but I always start with the facts.

Early in my career, I received two awards from the Arthritis Foundation, including a national volunteer citation in 1997 and another for founding a patient and family education day in 2004 that continues today. During my fellowship, I received a Physician Scientist Development Award from the American College of Rheumatology.

Additional recognitions include:

  • American College of Rheumatology Visiting Professor Award in 2015
  • Best Doctors in America from 2007 to present (2020)
  • America’s Best Physicians from 2016 to present (2020)
  • Castle Connolly Top Doctor from 2015 to present (2020)
  • Top Rheumatologist from Ohio Magazine in 2020
  • Ohio Top Doctor in 2020

Given the volume of patients that I see, I’m primarily involved in collaborative research. I participate in a substantial number of translational projects, most of which are characterized by determining if a candidate’s medication will successfully treat a specific disease. With other projects, I help identify the immunologic and molecular basis of groups of autoimmune and autoinflammatory diseases.

My participation in pediatric musculoskeletal ultrasound research helps advance the clinical capacity of important technology. I also work independently to identify and improve ways to deliver care, especially to geographic regions with poor or limited accessibility to my subspecialty.

In my free time, I contribute extensively to Cincinnati’s Christ Church Cathedral in various leadership positions, including developing and administering resources for those in great need from many causes. I also helped shape a prevention of gun violence initiative in our community that focuses on empowering capacity within neighborhoods.

I’ve participated in several service-related and medical mission trips throughout Appalachia and Honduras. When I’m not working, my passions are travel, photography, music and cultivating friendships. My adult daughters keep me on my toes, too.

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information


Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis. Ruperto, N; Brunner, HI; Pacheco-Tena, C; Louw, I; Vega-Cornejo, G; Spindler, AJ; Kingsbury, DJ; Schmeling, H; Borzutzky, A; Cuttica, R; et al. Rheumatology. 2021; 60:4495-4507.

Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. Ruperto, N; Brunner, HI; Ramanan, AV; Horneff, G; Cuttica, R; Henrickson, M; Anton, J; Boteanu, AL; Penades, IC; Minden, K; et al. Rheumatology. 2021; 60:4568-4580.

The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis. Aljaberi, N; Tronconi, E; Schulert, G; Grom, AA; Lovell, DJ; Huggins, JL; Henrickson, M; Brunner, HI. Pediatric Rheumatology. 2020; 18.

Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Brunner, HI; Abud-Mendoza, C; Viola, DO; Calvo Penades, I; Levy, D; Anton, J; Calderon, JE; Chasnyk, VG; Ferrandiz, MA; Keltsev, V; et al. Annals of the Rheumatic Diseases. 2020; 79:1340-1348.

Loss- or Gain-of-Function Mutations in ACOX1 Cause Axonal Loss via Different Mechanisms. Chung, H; Wangler, MF; Marcogliese, PC; Jo, J; Ravenscroft, TA; Zuo, Z; Duraine, L; Sadeghzadeh, S; Li-Kroeger, D; Schmidt, RE; et al. Neuron. 2020; 106:589-606.e6.

Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Rothwell, S; Chinoy, H; Lamb, JA; Miller, FW; Rider, LG; Wedderburn, LR; McHugh, NJ; Mammen, AL; Betteridge, ZE; Tansley, SL; et al. Annals of the Rheumatic Diseases. 2019; 78:996-1002.

American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus. Brunner, HI; Holland, MJ; Beresford, MW; Ardoin, SP; Appenzeller, S; Silva, CA; Flores, F; Aydin, PO A; Wenderfer, SE; Levy, DM; et al. Arthritis Care and Research. 2019; 71:579-590.

170 Safety and efficacy of subcutaneous tocilizumab in patients with systemic and polyarticular juvenile idiopathic arthritis. Ramanan, AV; Brunner, HI; Ruperto, N; Martini, A; Cuttica, RJ; Weiss, JE; Henrickson, M; Schmeling, H; Antón, J; Minden, K; et al. Rheumatology. 2019; 58.

Validation of the Cutaneous Lupus Erythematosus Disease Area and Severity Index and pSkindex27 for use in childhood-onset systemic lupus erythematosus. AlE'ed, A; Aydin, PO A; Al Mutairi, N; AlSaleem, A; Sonmez, HE; Henrickson, M; Huggins, JL; Ozen, S; Al-Mayouf, SM; Brunner, HI. Lupus Science and Medicine. 2018; 5.

A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus. Patel, ZH; Lu, X; Miller, D; Forney, CR; Lee, J; Lynch, A; Schroeder, C; Parks, L; Magnusen, AF; Chen, X; et al. Human Molecular Genetics. 2018; 27:2392-2404.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey